FindMyKOL
Clinical trialNCT07354477RecruitingPhase 2Interventional

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

SponsorQlaris Bio, Inc.Enrollment14Non-proliferative Diabetic Retinopathy (NPDR)Normal Tension Glaucoma (NTG)Open-angle Glaucoma (OAG)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Stanford University, Dept. of Ophthalmology

    Palo Alto, California, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

QLS-111 Ophthalmic Solution
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 Feb 2026
Primary completion
30 Sept 2026
Completion
30 Sept 2026
Last update posted
6 Jul 2026
Registered enrollment
14
Registry id
NCT07354477
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.